OTLK Reports $23.1M Net Loss, $0.38 EPS, LYTENAVA™ Sales Double QoQ in Europe, Seeks FDA Guidance on ONS-5010
Outlook Therapeutics, Inc. Common Stock · Now $0.73
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS